SCHEMBL3017534

SCHEMBL3017534

COc1cc(-c2csc(N3CCC(S(=O)(=O)c4cc(Cl)cc(Cl)c4)CC3)n2)cc(OC)c1OC

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 4/20 0.58
ALDH1A1 P00352 3/20 0.58
GAA P10253 2/20 0.58
MAPT P10636 7/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
RAB9A P51151 4/20 0.44
NPC1 O15118 2/20 0.44
G6PD P11413 1/20 0.40
RECQL P46063 2/20 0.40
KDM4E B2RXH2 1/20 0.40
NTSR1 P30989 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
HSD17B10 Q99714 2/20 0.39
USP2 O75604 1/20 0.39
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39
TUBA3C P0DPH7 1/20 0.39
TUBA1B P68363 1/20 0.39
TUBA4A P68366 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3008345 0.92 MAPK1 (0.56) MAPK1ALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL3016310 0.92 ALDH1A1 (0.53) MAPK1ALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL3003214 0.89 SMN1; SMN2 (0.59) MAPK1ALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL3019595 0.89 ALDH1A1 (0.54) MAPK1ALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL3020987 0.88 ALDH1A1 (0.52) MAPK1ALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL3010185 0.88 RAB9A (0.48) MAPK1ALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL2999860 0.88 SMN1; SMN2 (0.51) MAPK1ALDH1A1MAPTSMN1; SMN2RAB9A
SCHEMBL2999759 0.87 MAPK1 (0.57) MAPK1ALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL3013931 0.87 ALDH1A1 (0.57) MAPK1ALDH1A1GAAMAPTSMN1; SMN2
SCHEMBL3012579 0.87 ALDH1A1 (0.57) MAPK1ALDH1A1GAAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPK1 2767/4885ALDH1A1 3510/4885GAA 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.